WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005105791) INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/105791    International Application No.:    PCT/EP2005/004454
Publication Date: 10.11.2005 International Filing Date: 26.04.2005
Chapter 2 Demand Filed:    07.11.2005    
IPC:
C07D 209/08 (2006.01), C07D 209/12 (2006.01), C07D 209/30 (2006.01), C07D 401/06 (2006.01), C07D 403/06 (2006.01), C07D 409/06 (2006.01), C07D 413/06 (2006.01), C07D 413/10 (2006.01), C07D 417/06 (2006.01)
Applicants: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH) (For All Designated States Except US).
DEHMLOW, Henrietta [DE/DE]; (DE) (For US Only).
KUHN, Bernd [DE/CH]; (CH) (For US Only).
PANDAY, Narendra [FR/DE]; (DE) (For US Only).
RATNI, Hasane [FR/FR]; (FR) (For US Only).
SCHULZ-GASCH, Tanja [DE/CH]; (CH) (For US Only).
WRIGHT, Matthew, Blake [US/CH]; (CH) (For US Only)
Inventors: DEHMLOW, Henrietta; (DE).
KUHN, Bernd; (CH).
PANDAY, Narendra; (DE).
RATNI, Hasane; (FR).
SCHULZ-GASCH, Tanja; (CH).
WRIGHT, Matthew, Blake; (CH)
Agent: SALUD, Carlos; Grenzacherstrasse 124, CH-4070 Basel (CH)
Priority Data:
04101889.6 03.05.2004 EP
Title (EN) INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS
(FR) DERIVES D'INDOLYLE EN TANT QUE MODULATEURS DU RECEPTEUR X DU FOIE
Abstract: front page image
(EN)Compounds of formula (I) and pharmaceutically acceptable salts and pharmaceutically acceptable esters thereof, wherein R1, R2, R3, R4, R5, R6, A, m, n and p are defined as in claim 1. These compounds can be used as medicaments in the treatment of diseases such as artherosclerosis and diabetes.
(FR)L'invention concerne des composés représentés par la formule (I) ainsi que des sels pharmaceutiquement acceptables et des esters pharmaceutiquement acceptables de celle-ci, dans laquelle R1, R2, R3, R4, R5, R6, A, m, n et p sont tels que définis dans la revendication 1. Ces composés peuvent être utilisés en tant que médicaments dans le traitement de maladies telles que l'athérosclérose et le diabète.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)